Now let me run calibration searches to anchor the score.**Initial bracket: 2.5 – 4.5**

Now let me narrow within the bracket.Now I have enough information to write the complete review.

---

## Summary

The paper evaluates a set of small language models (SLMs, ≤3B) and small vision-language models against medically adapted large counterparts (7–9B) on two clinical NLP tasks: consumer health question summarization (MeQSum) and radiology report generation (MIMIC-CXR). The central claims are: (1) LoRA-fine-tuned SLMs can match or exceed large medical LLMs on summarization; (2) a "safety collapse" occurs at sub-1B parameter scales; and (3) small VLMs still lag behind large VLMs for radiology report generation. The paper introduces a "Collapse Analysis" framework (Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness) and a composite Readiness Score as a proposed methodological contribution.

---

## Strengths

- **Clinically motivated scaling analysis across multiple families**: The evaluation spans SmolLM2 (135M–3B) and Gemma-3 (270M–4B) variants plus LLaMA-3.2, providing a multi-family view of how performance degrades with scale. The sharp spike in hallucination rate at sub-1B scales (Table 3: 18.3% at SmolLM2-360M, 75% at Gemma-3-270M vs. ≤3.5% at ≥1.7B) is vivid and practically meaningful, even if how those numbers were computed is unexplained.

- **"Safety collapse" framing is useful**: The observation that sub-billion models exhibit qualitatively different failure modes (hallucination spike, instruction drift) rather than smooth degradation offers a conceptually useful framing for deployment decisions, regardless of the methodological gaps in operationalizing it.

- **Both adaptation strategies tested**: Testing zero-shot, few-shot ICL and LoRA/QLoRA/prompt-tuning on every small model provides a structured comparison of adaptation strategies for the SLM side of the study.

---

## Weaknesses

### Fatal
*None that fully invalidates the paper's existence as a study, but the major issues below collectively undermine the headline claim and the paper's most distinctive contribution.*

### Major

- **Asymmetric comparison invalidates the central headline finding.** The paper's primary headline claim — "After LoRA fine-tuning, all small LMs outperformed large LMs across every metric" (Section 4, Figure 3) — is built on a comparison where only the small models were fine-tuned. Figure 3 shows LoRA bars for Llama-3.2-1B, Gemma-3-1B, and SmolLM2-1.7B, but BioMistral-7B, Med-LLaMA-8B, and OpenBioLLM-8B appear only as ICL results with no LoRA bars. Since LoRA fine-tuning produces large gains for every small model (Gemma-3-1B BLEU: ~2.5% ICL → ~21.5% LoRA), there is no reason to assume the same adaptation would not lift the large-model baselines as well. The comparison cannot distinguish "small models are sufficient" from "fine-tuning matters more than scale." This is not a gap for future work — it is the comparison the paper's thesis requires.

- **Collapse Analysis framework lacks any measurement protocol.** Table 3 presents precise numeric values for Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness, and the composite Readiness Score. Yet nowhere in the paper is there a definition of how any of these values are computed. How is a hallucination identified — rule-based, LLM-judge, human annotation? What is Task Adherence's scoring rubric? What is the formula for the Readiness Score? The Introduction lists this framework explicitly as a contribution; without measurement definitions, the numbers in Table 3 are unverifiable assertions. The "safety collapse" claim and the "minimum viable scale" conclusion depend entirely on these numbers.

- **Internal contradiction in VLM results not acknowledged.** The paper concludes (Section 5, Finding 2) that "small VLMs consistently lag behind larger counterparts" in radiology report generation. However, Table 4 shows Qwen2.5-VL (3B, fine-tuned) achieving BERTScore 0.8146 vs. Med-Flamingo (9B) at 0.7100 — the small VLM outperforms the large one on this metric. Section 3.3 nonetheless asserts "both small VLMs remain below the large VLM baselines in all metrics," which is directly contradicted by the table. The paper makes no attempt to reconcile this.

### Minor

- **The ~1B safety threshold is stated more precisely than the data support.** The SmolLM2 family has measurements at 1.7B and 360M with nothing in between; Gemma-3 has 1B and 270M with nothing in between. More critically, the threshold is inconsistent across families: Gemma-3-1B already shows substantial degradation (Task Adherence: 0.70, Concept Recall: 0.55, Hallucination: 2.9%) while SmolLM2-1.7B remains largely stable. A single "~1B" threshold does not characterize both patterns faithfully.

- **Broken cross-reference.** Section 3.3 contains: "From Table ?? we can infer that fine-tuned Qwen 2.5-VL closes much of the gap…" — an unresolved reference indicating the manuscript was not complete at submission.

- **Decoding strategy ambiguity.** Section 3 describes three distinct stochastic decoding strategies (top-k=3, top-p=0.9, temperature=0.3) but does not state whether results are averaged across them, or the best strategy is selected per model. If the latter, it could selectively inflate scores for specific models.

- **No confidence intervals or significance testing.** The 250-sample test set is small enough that differences of 0.007 BERTScore (SmolLM2-1.7B 0.9007 vs. OpenBioLLM-8B 0.8938, Table 2) cannot be treated as meaningful without variance estimates. No variance is reported anywhere.

### Trivial
- The section citing SmolLM2's hallucination problem in fine-tuning receives only a parenthetical acknowledgment ("occasionally led to hallucinations in extreme cases"), which substantially undersells what Table 3 (SmolLM2-135M: 67.8% hallucination rate) shows about the model's instability.

---

## Nice-to-Haves

- Add at least one fine-tuned large LM baseline (e.g., BioMistral-7B LoRA on MeQSum) to Figure 3. If fine-tuned SLMs still outperform fine-tuned LLMs, the efficiency claim stands; if not, the key takeaway shifts to adaptation strategy rather than scale.
- Fully operationalize the Collapse Analysis: publish the annotation rubric/code, inter-annotator agreement for any human-judged components, and the formula for the Readiness Score. A named framework should be reproducible.
- Add intermediate model sizes (e.g., 600M) to sharpen the threshold estimate and reconcile the cross-family threshold inconsistency.
- Reconcile the BERTScore result for Qwen2.5-VL in Table 4 explicitly — if small VLMs can beat large ones on one metric, that nuance deserves discussion rather than suppression.

---

## Removed Points

*These points were considered but removed; treat them with caution.*

- **Reviewer claim that the paper does not acknowledge fine-tuned large LMs in the limitations section**: The Limitations section does not explicitly name this gap, but the scope is acknowledged. This is minor enough to be subsumed under the asymmetric comparison weakness above.
- **Strength Finder claim 3 ("Definitive gap in small VLMs")**: Removed as a strength because Table 4 directly contradicts the "consistently lag behind" claim for BERTScore (Qwen2.5-VL 0.8146 > Med-Flamingo 0.7100). A weakness wins over the claimed strength.
- **Harsh Critic claim about SmolLM2 BERTScore 0.9007 vs. OpenBioLLM 0.8938 being "0.7 pp" and presented as "small models rival large models"**: This is a legitimate concern but subsumed in the Minor weakness about no confidence intervals.
- **Harsh Critic claim that the Introduction contradicts itself by repositioning SLMs**: The repositioning in Section 2 ("context-grounded information extraction rather than open-ended clinical reasoning") is an honest scoping, not an internal contradiction. Removed.
- **Strength Finder claim about "comprehensive comparison of adaptation strategies"**: Partially valid but weakened because the large models were never fine-tuned. Moved to Removed rather than kept as a strength.

---

## Novel Insights

The most genuinely novel observation this paper surfaces — even if incompletely executed — is that model degradation below ~1B parameters is not gradual but discontinuous: models at 360M exhibit hallucination rates an order of magnitude higher than those at 1.7B. This "cliff" behavior (if confirmed with proper measurement protocols) would be more actionable for practitioners than a smooth scaling curve, because it defines a hard floor for safe deployment rather than a trade-off continuum. The paper is also the first to test both ICL and PEFT strategies on this size range in a paired fashion across two clinical tasks and two modalities, generating data on the VLM/LM split that is practically informative even if the analysis is incomplete.

---

## Suggestions

1. **Fine-tune at least BioMistral-7B with LoRA on MeQSum** and add it to Figure 3. This single experiment would either confirm or rebut the central finding.
2. **Publish the Collapse Analysis protocol** as a supplementary appendix: annotation instructions, any automated detection code for hallucinations, the formula for Readiness Score, and inter-annotator agreement if human annotation was used.
3. **Resolve the VLM contradiction**: acknowledge that Qwen2.5-VL leads on BERTScore but lags on other metrics, and give a principled explanation (e.g., BERTScore measures surface semantics differently from clinical precision captured by BLEU/ROUGE/MEDCON).
4. **Test intermediate sizes** (500M–800M) to sharpen the threshold estimate and resolve the cross-family inconsistency.
5. **Fix the broken reference** ("Table ??") in Section 3.3.

---

## Score and Decision

**Evaluation on key axes:**
- *Originality*: Moderate — the framing is useful ("safety collapse," minimum viable scale), but the experimental design is largely straightforward benchmarking.
- *Importance of research question*: Reasonable — practical deployment scale for clinical AI is a genuine concern.
- *Claims well-supported*: Weak — the headline claim rests on an asymmetric comparison; the signature contribution is operationally undefined.
- *Soundness of experiments*: Weak — asymmetric fine-tuning comparison, undefined measurement protocol, internal VLM contradiction.
- *Clarity of writing*: Mixed — readable but contains a broken cross-reference and contradicts itself on VLM results.
- *Value to research community*: Modest — the raw data on sub-1B collapse is interesting but not actionable without a reproducible protocol.

**Anchor comparison:**

| Anchor | Avg Score | Round | Comparison |
|--------|-----------|-------|-----------|
| `/deepreview_13k_calibration/K1bv86Uvbp.md` (LLMs for biomedical KG) | 3.00 | R1 | Benchmarking paper with methodology issues; similar class but has more models (12 LLMs) and a clearer (if limited) protocol |
| `/deepreview_13k_calibration/JiWlVYB4rh.md` (EchoQA) | 3.00 | R1 | Evaluation paper with unclear methodology; at least contributes a large dataset — this paper has no dataset contribution |
| `/deepreview_13k_calibration/Bx5kcMkb8l.md` (No Factor Left Behind) | 3.00 | R1 | Weak medical LLM paper; comparable in terms of methodological problems |
| `/deepreview_13k_calibration/nzh8Z8d1Zc.md` (o1 in Medicine preliminary) | 3.67 | R2 | Evaluation study with less critical flaws — that paper evaluates across 37 datasets with clearer protocols; stronger than this paper |
| `/deepreview_13k_calibration/jgVqCCg5XX.md` (Revisiting Scaling Effects) | 4.00 | R1/R2 | Has a new benchmark, a formula, more rigorous scaling analysis — clearly stronger |
| `/deepreview_13k_calibration/gYcft1HIaU.md` (Clinical Knowledge LLMs) | 4.33 | R1 | More rigorous evaluation with a knowledge-base contribution |
| `/deepreview_13k_calibration/o9SuQXZvNA.md` (ClinicalBench) | 5.50 | R1 | Introduces a proper benchmark, 14 LLMs + 8 medical LLMs + 11 ML models; far more comprehensive and methodologically sound |

**Bracketing**: Round 1 bracket: 2.5–4.5. Round 2 narrows to 2.5–3.5. The paper is weaker than the o1-in-Medicine preliminary study (3.67) which at least has a clear evaluation across 37 datasets, and weaker than the scaling-effects paper (4.0) which has a proper formula and scaling law analysis. It is comparable to EchoQA (3.0) and the biomedical KG paper (3.0) — both rejected for similar reasons (unclear/undefined methodology, limited rigor). The paper's central comparison is fatally asymmetric, and its most novel contribution (the Collapse Analysis) is entirely undefined operationally, making it neither reproducible nor verifiable. The broken cross-reference and internal VLM contradiction further indicate the manuscript is incomplete. I score this at **3.0**.

MY FINAL SCORE: <score>3.0</score>
MY FINAL DECISION: <decision>Reject</decision>